Explore types of diabetes medication, how they work, benefits, and side effects to make informed choices for better diabetes ...

It's also worth noting that ex-GLP 1 subgrowth would have been 40% ... subscribers are now using personalized products (50.4%, versus 42.1% in Q2): which, in my view, should improve the company's ...

"As a reminder, Part 1 of this Phase 2a trial is exploring DA-1241 compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in combination with sitagliptin, a DPP-4 inhibitor ...

all-natural supplement formulated to address pervasive gut-related side effects of glucagon-like peptide 1 (GLP-1) medications, including popular weight-loss drugs like Ozempic ®, Wegovy ...

taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent ...

Given these results, the researchers recommend that doctors consider prescribing newer diabetes medications after metformin, such as GLP-1 agonists, SGLT-2 inhibitors, or DPP-4 inhibitors ...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the ...

DPP has had a lasting ... For some patients, a combination of metformin and lifestyle changes might be best. In recent years, a class of drugs called GLP-1 drugs has become widely available ...

taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent ...

taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent ...

“The BIO-Europe conference offers an ideal opportunity to highlight our latest clinical findings, including the positive data from our GLP-1 combination study,” said Ivor Elrifi, CEO of ...